In addition to the potential predictive role of BRCA1, BRCA1 overexpression confers aggressive behavior in transgenic models of small cell and squamous cell lung carcinomas, as well as in a subset of lung adenocarcinomas harboring the intrinsic T/t-antigen cancer signature.[30] Poor prognosis has also been associated with BRCA1 overexpression in early NSCLC.[31] In the present study, two-year survival was 41% in patients with the lowest levels of BRCA1, 16% in those with intermediate levels and 0% in those with the highest levels. The gene discussed is BRCA1; the disease is cancer.